Arch Biopartners Inc. (ARCH.V)
CAD 1.7
(-2.86%)
CAD 1.7
(-2.86%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.18 Million CAD | 7.13% |
| 2022 | 3.9 Million CAD | -17.16% |
| 2021 | 4.71 Million CAD | 72.31% |
| 2020 | 2.73 Million CAD | 10.14% |
| 2019 | 2.48 Million CAD | 164.64% |
| 2018 | 938.93 Thousand CAD | 205.97% |
| 2017 | 306.86 Thousand CAD | 135.38% |
| 2016 | 130.37 Thousand CAD | 144.56% |
| 2015 | -292.54 Thousand CAD | -2413.49% |
| 2014 | -11.63 Thousand CAD | -103.14% |
| 2013 | 370.55 Thousand CAD | 616.48% |
| 2012 | -71.74 Thousand CAD | 65.1% |
| 2011 | -205.56 Thousand CAD | 59.39% |
| 2010 | -506.24 Thousand CAD | -31739.56% |
| 2009 | -1590.00 CAD | -100.1% |
| 2008 | 1.64 Million CAD | 21.43% |
| 2007 | 1.35 Million CAD | 45.57% |
| 2006 | 928.52 Thousand CAD | -12.28% |
| 2005 | 1.05 Million CAD | -6.22% |
| 2004 | 1.12 Million CAD | 85.65% |
| 2003 | 607.98 Thousand CAD | 4342814.29% |
| 2002 | -14.00 CAD | -100.01% |
| 2001 | 116.85 Thousand CAD | 265.92% |
| 2000 | -70.42 Thousand CAD | -22117.03% |
| 1999 | -317.00 CAD | 25.24% |
| 1998 | -424.00 CAD | 90.79% |
| 1997 | -4604.00 CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 5.28 Million CAD | 3.07% |
| 2024 Q2 | 5.12 Million CAD | 8.21% |
| 2024 Q1 | 4.73 Million CAD | 13.12% |
| 2023 Q4 | 4.18 Million CAD | 16.86% |
| 2023 FY | 4.18 Million CAD | 7.13% |
| 2023 Q2 | 5.21 Million CAD | 23.2% |
| 2023 Q1 | 4.23 Million CAD | 8.32% |
| 2023 Q3 | 3.58 Million CAD | -31.31% |
| 2022 Q1 | 3.67 Million CAD | -22.03% |
| 2022 Q4 | 3.9 Million CAD | 2.74% |
| 2022 FY | 3.9 Million CAD | -17.16% |
| 2022 Q2 | 3.62 Million CAD | -1.3% |
| 2022 Q3 | 3.8 Million CAD | 4.77% |
| 2021 Q1 | 2.8 Million CAD | 2.54% |
| 2021 Q2 | 3.26 Million CAD | 16.37% |
| 2021 Q3 | 5.58 Million CAD | 70.87% |
| 2021 Q4 | 4.71 Million CAD | -15.49% |
| 2021 FY | 4.71 Million CAD | 72.31% |
| 2020 Q3 | 2.01 Million CAD | -36.35% |
| 2020 FY | 2.73 Million CAD | 10.14% |
| 2020 Q1 | 2.84 Million CAD | 14.54% |
| 2020 Q2 | 3.17 Million CAD | 11.4% |
| 2020 Q4 | 2.73 Million CAD | 35.61% |
| 2019 Q2 | 1.86 Million CAD | 55.82% |
| 2019 Q4 | 2.48 Million CAD | 19.09% |
| 2019 Q3 | 2.08 Million CAD | 11.74% |
| 2019 Q1 | 1.19 Million CAD | 27.63% |
| 2019 FY | 2.48 Million CAD | 164.64% |
| 2018 Q1 | 678.89 Thousand CAD | 121.23% |
| 2018 FY | 938.93 Thousand CAD | 205.97% |
| 2018 Q3 | 158.14 Thousand CAD | 22.11% |
| 2018 Q2 | 129.5 Thousand CAD | -80.92% |
| 2018 Q4 | 938.93 Thousand CAD | 493.73% |
| 2017 Q3 | 302.06 Thousand CAD | 472.7% |
| 2017 Q1 | 277.5 Thousand CAD | 112.86% |
| 2017 Q2 | 52.74 Thousand CAD | -80.99% |
| 2017 Q4 | 306.86 Thousand CAD | 1.59% |
| 2017 FY | 306.86 Thousand CAD | 135.38% |
| 2016 Q4 | 130.37 Thousand CAD | 245.47% |
| 2016 Q3 | -89.62 Thousand CAD | -245.19% |
| 2016 Q2 | 61.72 Thousand CAD | 159.64% |
| 2016 Q1 | -103.5 Thousand CAD | 64.62% |
| 2016 FY | 130.37 Thousand CAD | 144.56% |
| 2015 Q3 | -390.19 Thousand CAD | 29.88% |
| 2015 Q4 | -292.54 Thousand CAD | 25.03% |
| 2015 Q1 | 81 Thousand CAD | 796.0% |
| 2015 Q2 | -556.46 Thousand CAD | -786.94% |
| 2015 FY | -292.54 Thousand CAD | -2413.49% |
| 2014 Q1 | 22.58 Thousand CAD | -93.9% |
| 2014 Q4 | -11.63 Thousand CAD | -106.34% |
| 2014 Q3 | 183.45 Thousand CAD | 63.44% |
| 2014 Q2 | 112.24 Thousand CAD | 396.93% |
| 2014 FY | -11.63 Thousand CAD | -103.14% |
| 2013 Q4 | 370.55 Thousand CAD | -3.71% |
| 2013 FY | 370.55 Thousand CAD | 616.48% |
| 2013 Q3 | 384.81 Thousand CAD | 3.55% |
| 2013 Q2 | 371.62 Thousand CAD | 1660.91% |
| 2013 Q1 | -23.8 Thousand CAD | 66.82% |
| 2012 Q3 | -143.53 Thousand CAD | -54.11% |
| 2012 FY | -71.74 Thousand CAD | 65.1% |
| 2012 Q1 | -135.18 Thousand CAD | 34.24% |
| 2012 Q2 | -93.13 Thousand CAD | 31.11% |
| 2012 Q4 | -71.74 Thousand CAD | 50.01% |
| 2011 Q2 | -349.85 Thousand CAD | 24.57% |
| 2011 FY | -205.56 Thousand CAD | 59.39% |
| 2011 Q3 | -299.65 Thousand CAD | 14.35% |
| 2011 Q1 | -463.82 Thousand CAD | 8.38% |
| 2011 Q4 | -205.56 Thousand CAD | 31.4% |
| 2010 FY | -506.24 Thousand CAD | -31739.56% |
| 2010 Q4 | -506.24 Thousand CAD | 20.92% |
| 2010 Q2 | -87.00 CAD | 94.53% |
| 2010 Q1 | -1590.00 CAD | 86.17% |
| 2010 Q3 | -640.18 Thousand CAD | -735745.98% |
| 2009 FY | -1590.00 CAD | -100.1% |
| 2009 Q1 | 1.64 Million CAD | -47.92% |
| 2009 Q2 | 1.18 Million CAD | -27.54% |
| 2009 Q4 | -11.5 Thousand CAD | -1043.14% |
| 2009 Q3 | -1006.00 CAD | -100.08% |
| 2008 FY | 1.64 Million CAD | 21.43% |
| 2008 Q1 | 1.35 Million CAD | -21.75% |
| 2008 Q2 | 1.98 Million CAD | 46.61% |
| 2008 Q3 | 2.33 Million CAD | 18.07% |
| 2008 Q4 | 3.15 Million CAD | 34.7% |
| 2007 Q3 | 995.57 Thousand CAD | 4.47% |
| 2007 Q1 | 928.52 Thousand CAD | -12.8% |
| 2007 Q2 | 953.02 Thousand CAD | 2.64% |
| 2007 FY | 1.35 Million CAD | 45.57% |
| 2007 Q4 | 1.72 Million CAD | 73.5% |
| 2006 FY | 928.52 Thousand CAD | -12.28% |
| 2006 Q4 | 1.06 Million CAD | 14.64% |
| 2006 Q3 | 928.84 Thousand CAD | -6.63% |
| 2006 Q2 | 994.81 Thousand CAD | -6.02% |
| 2006 Q1 | 1.05 Million CAD | 1.17% |
| 2005 Q4 | 1.04 Million CAD | 14.41% |
| 2005 Q3 | 914.56 Thousand CAD | -10.23% |
| 2005 Q2 | 1.01 Million CAD | -9.74% |
| 2005 Q1 | 1.12 Million CAD | -3.28% |
| 2005 FY | 1.05 Million CAD | -6.22% |
| 2004 Q3 | 1.24 Million CAD | 50.79% |
| 2004 Q1 | 607.98 Thousand CAD | 1066731.58% |
| 2004 Q2 | 823.09 Thousand CAD | 35.38% |
| 2004 FY | 1.12 Million CAD | 85.65% |
| 2004 Q4 | 1.16 Million CAD | -5.97% |
| 2003 Q4 | -57.00 CAD | 99.77% |
| 2003 Q3 | -25.26 Thousand CAD | -114718.18% |
| 2003 Q2 | -22.00 CAD | -57.14% |
| 2003 Q1 | -14.00 CAD | -100.03% |
| 2003 FY | 607.98 Thousand CAD | 4342814.29% |
| 2002 FY | -14.00 CAD | -100.01% |
| 2002 Q4 | 49.56 Thousand CAD | 5.32% |
| 2002 Q2 | -23.68 Thousand CAD | -120.27% |
| 2002 Q3 | 47.05 Thousand CAD | 298.69% |
| 2002 Q1 | 116.85 Thousand CAD | 0.0% |
| 2001 Q1 | -70.42 Thousand CAD | 0.0% |
| 2001 Q2 | -49.19 Thousand CAD | 30.15% |
| 2001 Q3 | -22.71 Thousand CAD | 53.83% |
| 2001 FY | 116.85 Thousand CAD | 265.92% |
| 2000 FY | -70.42 Thousand CAD | -22117.03% |
| 2000 Q1 | -317.00 CAD | 0.0% |
| 1999 Q1 | -424.00 CAD | 87.62% |
| 1999 FY | -317.00 CAD | 25.24% |
| 1998 FY | -424.00 CAD | 90.79% |
| 1998 Q4 | -3425.00 CAD | 49.48% |
| 1998 Q2 | -321.00 CAD | 0.0% |
| 1998 Q3 | -6780.00 CAD | -2012.15% |
| 1997 FY | -4604.00 CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Covalon Technologies Ltd. | -7.23 Million CAD | 157.865% |
| Hemostemix Inc. | 4.16 Million CAD | -0.452% |
| Universal Ibogaine Inc. | 1.01 Million CAD | -313.682% |
| Kane Biotech Inc. | 7.52 Million CAD | 44.399% |
| MedMira Inc. | 9.25 Million CAD | 54.797% |
| Marvel Biosciences Corp. | 443.37 Thousand CAD | -843.871% |
| NervGen Pharma Corp. | -11.46 Million CAD | 136.51% |
| XORTX Therapeutics Inc. | -4.53 Million CAD | 192.364% |